Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

@article{Palumbo2016DaratumumabBA,
  title={Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.},
  author={Antonio Palumbo and Asher Alban Chanan-Khan and Katja C. Weisel and Ajay Nooka and Tamas Masszi and Meral Beksac and Ivan {\vS}pi{\vc}ka and Vania Tietsch de Moraes Hungria and Markus Munder and Mar{\'i}a Victoria Mateos and Tomer M. Mark and Ming Qi and Jordan M. Schecter and Himal Amin and Xiang Qin and William Deraedt and Tahamtan Ahmadi and Andrew Spencer and P. Sonneveld},
  journal={The New England journal of medicine},
  year={2016},
  volume={375 8},
  pages={754-66}
}
BACKGROUND Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in combination with bortezomib in patients with newly diagnosed multiple myeloma. METHODS In this phase 3 trial, we randomly assigned 498 patients with relapsed or relapsed and refractory multiple myeloma to receive bortezomib (1.3 mg per square meter of… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 119 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 117 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

Journal of the National Comprehensive Cancer Network : JNCCN • 2018

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

Journal of the National Comprehensive Cancer Network : JNCCN • 2016

Similar Papers

Loading similar papers…